Total Payments
$486,009
2024 Payments
$53,307
Companies
31
Transactions
537
Medicare Patients
1,118
Medicare Billing
$165,968
Payment Breakdown by Category
Consulting$206,262 (42.4%)
Other$140,738 (29.0%)
Research$111,293 (22.9%)
Travel$20,589 (4.2%)
Food & Beverage$7,126 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $206,262 | 72 | 42.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $114,033 | 42 | 23.5% |
| Unspecified | $111,293 | 263 | 22.9% |
| Honoraria | $22,205 | 8 | 4.6% |
| Travel and Lodging | $20,589 | 54 | 4.2% |
| Food and Beverage | $7,126 | 97 | 1.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,500 | 1 | 0.9% |
Payments by Type
General
$374,716
274 transactions
Research
$111,293
263 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $102,416 | 69 | $0 (2024) |
| Astellas Pharma Global Development | $70,695 | 244 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $70,166 | 44 | $0 (2024) |
| AstraZeneca UK Limited | $52,047 | 22 | $0 (2024) |
| Merck Sharp & Dohme LLC | $45,896 | 24 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $34,972 | 43 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $28,990 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $13,671 | 6 | $0 (2024) |
| Astellas Pharma US Inc | $11,629 | 2 | $0 (2022) |
| GENZYME CORPORATION | $9,183 | 12 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $53,307 | 36 | PFIZER INC. ($17,518) |
| 2023 | $81,640 | 53 | AstraZeneca Pharmaceuticals LP ($26,437) |
| 2022 | $59,070 | 76 | AstraZeneca UK Limited ($16,138) |
| 2021 | $67,606 | 66 | PFIZER INC. ($20,810) |
| 2020 | $52,431 | 63 | Merck Sharp & Dohme Corporation ($9,091) |
| 2019 | $69,188 | 128 | Astellas Pharma Global Development ($27,262) |
| 2018 | $47,526 | 49 | Bayer HealthCare Pharmaceuticals Inc. ($15,640) |
| 2017 | $55,241 | 66 | Dendreon Pharmaceuticals LLC ($21,391) |
All Payment Transactions
537 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | PFIZER INC. | XTANDI (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: XTANDI CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/08/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $139.46 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | — | Consulting Fee | Cash or cash equivalent | $1,053.00 | General |
| 09/15/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $147.14 | General |
| Category: ONCOLOGY | ||||||
| 09/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | — | Cash or cash equivalent | $3,614.17 | Research |
| Study: Research Publication/ Writing Support • Category: Oncology | ||||||
| 08/23/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $4,110.00 | General |
| 06/19/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 06/19/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 06/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $1,905.00 | General |
| Category: Oncology | ||||||
| 06/04/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $26.82 | General |
| Category: Oncology | ||||||
| 06/03/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 06/03/2024 | Astellas Pharma Global Development | Xtandi (Drug) | Food and Beverage | In-kind items and services | $31.96 | General |
| Category: Oncology | ||||||
| 06/02/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $47.28 | General |
| 06/01/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $42.43 | General |
| Category: HORMONE THERAPY | ||||||
| 05/31/2024 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,920.00 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $135.00 | General |
| 05/31/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: ONCOLOGY | ||||||
| 05/31/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: ONCOLOGY | ||||||
| 04/29/2024 | Merck Sharp & Dohme LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| 04/28/2024 | PFIZER INC. | TALZENNA (Drug), XTANDI | Food and Beverage | In-kind items and services | $145.96 | General |
| Category: ONCOLOGY | ||||||
| 04/26/2024 | PFIZER INC. | TALZENNA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $730.00 | General |
| Category: ONCOLOGY | ||||||
| 04/10/2024 | PFIZER INC. | — | — | In-kind items and services | $1,400.00 | Research |
| Study: NON PRODUCT CLINICAL PUBLICATION PROGRAM | ||||||
| 03/27/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Consulting Fee | Cash or cash equivalent | $476.25 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $17,180 | 17 |
| A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY ADT VERSUS PLACEBO PLUS ADT IN PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER MHSPC | Astellas Pharma Global Development | $15,557 | 58 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $14,396 | 63 |
| DAROL: Darolutamide Observational Study in castration resistant prostate cancer patients | Bayer Healthcare Pharmaceuticals Inc. | $13,363 | 4 |
| A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $8,119 | 34 |
| A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $6,836 | 41 |
| NON PRODUCT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $6,000 | 3 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $5,820 | 1 |
| Review Article | Novartis Pharmaceuticals Corporation | $4,145 | 1 |
| Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study | Astellas Pharma Global Development | $4,112 | 6 |
| Research Publication/ Writing Support | Novartis Pharmaceuticals Corporation | $3,614 | 1 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy ADT Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer mHSPC | Astellas Pharma Global Development | $2,697 | 11 |
| Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer CRPC trials | Astellas Pharma Global Development | $1,699 | 3 |
| PROSPER A MULTINATIONAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER | Astellas Pharma Global Development | $1,133 | 4 |
| Effect of enzalutamide on patient-reported outcomes, including fatigue, in metastatic hormone-sensitive prostate cancer: analyses from the arches study | Astellas Pharma Global Development | $715.39 | 2 |
| NMA analysis | Astellas Pharma Global Development | $399.43 | 1 |
| Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZA) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study. | Astellas Pharma Global Development | $393.46 | 2 |
| A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) | Astellas Pharma Global Development | $374.00 | 1 |
| 9785-CL-0335 | Astellas Pharma Global Development | $310.67 | 1 |
| Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy | Astellas Pharma Global Development | $301.00 | 1 |
| The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups | Astellas Pharma Global Development | $273.53 | 1 |
| IMPACT OF ENZALUTAMIDE ENZA VS. BICALUTAMIDE BIC ON HEALTH-R | Astellas Pharma Global Development | $184.00 | 2 |
| Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC): STRIVE study | Astellas Pharma Global Development | $114.13 | 1 |
| Real-world treatment patterns in patients with metastatic castration-sensitive prostate cancer in the US | Astellas Pharma Global Development | $25.18 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 222 | 336 | $124,782 | $34,534 |
| 2022 | 3 | 272 | 419 | $150,913 | $41,047 |
| 2021 | 4 | 308 | 496 | $176,015 | $50,629 |
| 2020 | 5 | 316 | 512 | $176,719 | $39,759 |
Total Patients
1,118
Total Services
1,763
Medicare Billing
$165,968
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 159 | 273 | $93,912 | $26,859 | 28.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 63 | 63 | $30,870 | $7,674 | 24.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 196 | 340 | $117,106 | $32,115 | 27.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 57 | 57 | $27,930 | $7,423 | 26.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 22 | $5,877 | $1,508 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 212 | 399 | $137,256 | $39,993 | 29.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 66 | 66 | $32,386 | $8,412 | 26.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 19 | 20 | $5,100 | $1,441 | 28.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 11 | 11 | $1,273 | $782.60 | 61.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 201 | 391 | $134,504 | $29,097 | 21.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 57 | 57 | $27,930 | $6,636 | 23.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 30 | 35 | $8,925 | $1,890 | 21.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 12 | 13 | $3,536 | $1,149 | 32.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 16 | 16 | $1,824 | $986.51 | 54.1% |
About Dr. Andrew Armstrong, MD
Dr. Andrew Armstrong, MD is a Medical Oncology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1528160199.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Andrew Armstrong, MD has received a total of $486,009 in payments from pharmaceutical and medical device companies, with $53,307 received in 2024. These payments were reported across 537 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($206,262).
As a Medicare-enrolled provider, Armstrong has provided services to 1,118 Medicare beneficiaries, totaling 1,763 services with total Medicare billing of $165,968. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Durham, NC
- Active Since 09/02/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1528160199
Products in Payments
- XTANDI (Drug) $91,006
- Xofigo (Drug) $44,238
- LYNPARZA (Drug) $43,941
- PROVENGE (Drug) $40,324
- TALZENNA (Drug) $27,866
- Xtandi (Drug) $21,586
- Nubeqa (Drug) $17,850
- JEVTANA (Drug) $8,384
- SUTENT (Drug) $6,907
- OPDIVO (Biological) $6,631
- ENZALUTAMIDE (Drug) $6,481
- PLUVICTO (Drug) $3,661
- Lenvima (Drug) $3,500
- ERLEADA (Drug) $3,488
- CABOMETYX (Drug) $2,837
- Rubraca (Drug) $2,419
- ILLUCCIX (Drug) $1,500
- TECENTRIQ (Biological) $1,292
- NO PRODUCT DISCUSSED (Drug) $1,006
- Enzalutamide (Drug) $938.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Durham
Dr. Thomas Leblanc, Md, Ma, MD, MA
Medical Oncology — Payments: $1.5M
Medical Oncology $1.5M
Neal Ready, Md, MD
Medical Oncology — Payments: $383,286
Medical Oncology $383,286
Dr. Michael Harrison, M.d, M.D
Medical Oncology — Payments: $276,555
Medical Oncology $276,555
Nelson Chao, Md, MD
Medical Oncology — Payments: $79,858
Medical Oncology $79,858
Dr. Sundhar Ramalingam, M.d, M.D
Medical Oncology — Payments: $68,550
Medical Oncology $68,550
Dr. Gerard Blobe, M.d, M.D
Medical Oncology — Payments: $55,242
Medical Oncology $55,242